Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriers

Fig. 3

Screening of the optimal co-treatment ratio between docetaxel (DTX)-loaded PEGylated and RIPL peptide-conjugated nanostructured lipid carriers (DTX-P/R-NLCs) DTX-P/R-NLCs and curcumin (CUR)-loaded P/R-NLCs (CUR-P/R-NLCs) for MCF7 and MCF7/ADR cells. A Plot of the combination index (CI) against fractional growth inhibition (Fa). B Comparison of CI values at Fa = 0.5 (CI50)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us